SGLT2 inhibitor-induced glycosuria improves steatotic liver disease in parallel with enhanced ureagenesis in ob/ob mice
Our data suggest that enhanced hepatic ureagenesis as a compensatory water conservation mechanism for glycosuria-induced fluid loss may be associated with amelioration of steatotic liver disease in SGLT2 inhibitor-treated ob/ob mice.
Authors
- Yoshio Konishi (ORCID: https://orcid.org/0009-0006-2029-8977)
- Satoshi Kidoguchi
- Hiroyuki Ohsaki
- Jens Marc Titze (ORCID: https://orcid.org/0000-0001-8463-8404)
- Takashi Morikawa (ORCID: https://orcid.org/0000-0003-4445-9270)
- Daisuke Yamazaki (ORCID: https://orcid.org/0000-0003-4981-3056)
- ASAHIRO MORISHITA
- Takashi Yokoo
- Kazuo Takahashi
- Yudai Tsuji
- Akira Nishiyama
- Kento Kitada
- Hideki Kobara
Institutions
- Jikei University School of Medicine (JP)
- Fujita Health University (JP)
- Kagawa University (JP)
- Osaka City General Hospital (JP)
- Duke Medical Center (US)
- Kobe University (JP)
Publication Details
- Journal
- Journal of Pharmacological Sciences
- Published
- 2025-12-25
- DOI
- https://doi.org/10.1016/j.jphs.2025.12.006
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00